Evaluating the usefulness of automatic continuous positive airway pressure (CPAP) in treating the sleep apnea-hypopnea syndrome (SAHS) is not easy because the algorithms for automatic CPAP implemented in the devices available are not well known and are probably dependent on the device. In addition, at present it is not possible to test the behavior of automatic CPAP devices in response to well-defined breathing patterns. Our aim was to implement a bench test to characterize the responses of automatic CPAP devices by subjecting them to breathing patterns of patients with SAHS. To this end, a variety of typical breathing patterns (normal, apneas, hypopneas, flow limitation, snoring) previously recorded in patients with SAHS during sleep were reproduced by a breathing waveform generator. Five commercially available automatic CPAP devices were tested. The responses of the devices to apneas, hypopneas, flow limitation, and snoring were considerably different. In some devices, the response was modified by air leaks similar to the ones found in patients. Consequently, the effectiveness of automatic CPAP assessed in clinical tests performed by using particular devices has no general validity. Testing automatic CPAP devices in a bench study is a useful first step in evaluating the performance of this new type of device in adjusting nasal pressure for each patient.

BackgroundReduced plasma nitrate (NOx) levels and increased urinary norepinephrine (U-NE) levels have been described in severe obstructive sleep apnea (OSA), and are reverted by continuous positive airway pressure (CPAP). The effect of CPAP on these biomarkers in mild-moderate OSA is not well understood.The aim of this study was to compare NOx and U-NE levels and blood pressure (BP) between male patients with mild-moderate and severe OSA and determine the impact of 1 month of CPAP therapy on these parameters.MethodsWe undertook a prospective study of 67 consecutive OSA patients (36 mild-moderate, 31 severe). Measurements of plasma NOx at 11 pm, 4 am and 7 am, 24-h U-NE and ambulatory BP were obtained at baseline and after 1 month of CPAP.ResultsAt baseline, NOx levels showed a significant decrease during the night in both groups (p < 0.001). U-NE level and BP were significantly higher in the severe OSA group. After 1 month of CPAP, there was a significant increase in NOx levels and a reduction in U-NE level and BP only in patients with severe OSA.ConclusionsOne month of CPAP results in significant improvements in NOx levels, 24-h U-NE level and BP in patients with severe OSA, but not in patients with mild-moderate OSA.Trial registrationClinicalTrials.gov: http://NCT01769807

Acellular bronchoalveolar lavage (BAL) proteomics can partially separate lung cancer from non-lung cancer patients based on principal component analysis and multivariate analysis. Furthermore, the variance in the proteomics data sets is correlated mainly with lung cancer status and, to a lesser extent, smoking status and gender. Despite these advances BAL small and large extracellular vehicles (EVs) proteomes reveal aberrant protein expression in paracrine signaling mechanisms in cancer initiation and progression. We consequently present a case-control study of 24 bronchoalveolar lavage extracellular vesicle samples which were analyzed by state-of-the-art liquid chromatography-mass spectrometry (LC-MS). We obtained evidence that BAL EVs proteome complexity correlated with lung cancer stage 4 and mortality within two years´ follow-up (p value = 0.006). The potential therapeutic target DNMT3B complex is significantly up-regulated in tumor tissue and BAL EVs. The computational analysis of the immune and fibroblast cell markers in EVs suggests that patients who deceased within the follow-up period display higher marker expression indicative of innate immune and fibroblast cells (four out of five cases). This study provides insights into the proteome content of BAL EVs and their correlation to clinical outcomes.